# Infectious Diseases Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN
- Date: 2026-02-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Priyanka Rao, MD
- Calendar frame: modern shifted

- Requested by: Vivian Tolliver, MD

## Reason for consultation

HIV infection diagnosed four months ago with cerebral toxoplasmosis and a CD4 count of 58, in a 45-year-old man who also has coronary artery disease after two bypass operations. Please review his antiretroviral regimen and its interactions with his cardiac medicines, and advise on opportunistic-infection prophylaxis, the monitoring schedule, and vaccines, so that we can co-manage his care. **S**

## History

Mr. Ashe, a 45-year-old man, is seen at the request of Dr. Tolliver for co-management of HIV. HIV was diagnosed four months ago when he presented with right-hand weakness from cerebral toxoplasmosis, confirmed by stereotactic biopsy; the CD4 count was 58 and the viral load 186,000 copies/mL. He completed six weeks of pyrimethamine, sulfadiazine, and leucovorin and has taken trimethoprim-sulfamethoxazole double strength twice daily since. He started bictegravir, emtricitabine, and tenofovir alafenamide two weeks into toxoplasmosis treatment and has missed no doses. He has had no headache, seizure, fever, rash, or cough, and his right hand has recovered. He acquired HIV, he understands, from a blood transfusion during his second bypass operation; the hospital reported the suspected transfusion-transmitted infection to the blood supplier at diagnosis. He has coronary artery disease after two bypass operations and has no angina. He is clear that he alone decides who learns of his diagnosis. **S**

## Examination

| System | Finding |
|---|---|
| General | Well and composed; weight 72.6 kg; blood pressure 116/72 |
| Mouth | No thrush or oral hairy leukoplakia |
| Lymph nodes | No enlarged nodes |
| Skin | No rash |
| Neurological | Grip strength and fine finger movements equal on both sides; no focal deficit |

BP 116/72 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 72.6 kg; BMI 21.2 kg/m². All vital signs are synthetic.

## Data reviewed

Hospital records, including the MRI, the biopsy report, the baseline genotype, and the hepatitis, tuberculosis, and Toxoplasma serologies. Dr. Tolliver's intake note four weeks ago, with the viral load (42 copies/mL), CD4 count (156), blood count, metabolic panel, ALT, lipid panel, and ECG. Today's metabolic panel, below. Sodium: 140 mmol/L; Potassium: 4.8 mmol/L; Creatinine: 1.16 mg/dL; eGFR: 79 mL/min/1.73 m²; Glucose: 90 mg/dL. All results are synthetic.

## Assessment

1. **HIV infection on antiretroviral therapy** (B20). Responding well: the viral load has fallen from 186,000 to 42 copies/mL in about 15 weeks and should become undetectable within the next few months, and the CD4 count has risen from 58 to 156. Bictegravir with emtricitabine and tenofovir alafenamide is a recommended first regimen, has a high barrier to resistance, and has no meaningful interaction with aspirin, atorvastatin, ezetimibe, or nitroglycerin. A regimen boosted with ritonavir or cobicistat would raise atorvastatin levels and limit its dose, efavirenz would lower them, and abacavir has been associated with myocardial infarction and should be avoided in a man with coronary disease. **S**
2. **Cerebral toxoplasmosis on maintenance therapy** (B58.2). Clinically resolved. Trimethoprim-sulfamethoxazole double strength twice daily is an accepted maintenance regimen and also prevents Pneumocystis pneumonia. It can stop once the CD4 count has been above 200 for more than six months on ART with a suppressed viral load, provided he remains free of symptoms. Prophylaxis for Mycobacterium avium complex is not needed, because he started fully active ART promptly. **S**
3. **Creatinine**. The rise from 0.98 to about 1.17 mg/dL is expected and stable. Both bictegravir and trimethoprim block tubular secretion of creatinine without lowering the true filtration rate. Potassium is high-normal on trimethoprim and should be watched. **S**
4. **Vaccines**. Inactivated vaccines can be given at any CD4 count, although responses are better as the count recovers. Live vaccines are contraindicated while the CD4 count is below 200; he is immune to measles, mumps, rubella, and varicella and needs none. **S**
5. **Coronary artery disease and HIV** (I25.10). HIV raises cardiovascular risk independently, which strengthens rather than changes the secondary-prevention plan: high-intensity atorvastatin with ezetimibe to an LDL below 55 mg/dL, aspirin, and blood pressure below 130/80. Integrase inhibitors can cause weight gain, which should be tracked. **S**

## Recommendations

1. Continue bictegravir, emtricitabine, and tenofovir alafenamide once daily; take it two hours before or six hours after any antacid, calcium, iron, or magnesium.
2. Avoid abacavir, ritonavir- or cobicistat-boosted regimens, and efavirenz; check any new medicine for interactions with the HIV regimen and with atorvastatin.
3. Continue trimethoprim-sulfamethoxazole double strength twice daily; stop it when the CD4 count has been above 200 for more than six months with an undetectable viral load and no symptoms, and restart it if the count falls below 200.
4. No Mycobacterium avium complex prophylaxis.
5. Viral load and CD4 count every three months until the CD4 count is stably above 200 and prophylaxis has stopped, then every three to six months.
6. Blood count, potassium, and creatinine every three months while on trimethoprim-sulfamethoxazole; ALT every six months; lipids per the coronary plan; urine albumin-to-creatinine ratio with the three-month blood tests and then yearly on tenofovir alafenamide, as it was not done at the start of therapy.
7. Second hepatitis B vaccine dose today and a surface antibody check one to two months later; second meningococcal ACWY dose at least eight weeks after the first; recombinant zoster vaccine, two doses; influenza and COVID-19 vaccines each autumn; no live vaccines.
8. Keep atorvastatin 80 mg and the ezetimibe added today, with an LDL goal below 55 mg/dL; track weight on the integrase inhibitor.
9. Anal cancer screening and colorectal cancer screening from age 45, at his preventive visit.
10. Share results with him alone, by secure message, unless he asks otherwise; peer support and counseling are available when he wants them.

## Strengths and supports

- Supports: married, with a young child, and close friends; has told only a few people about his HIV diagnosis **S**

## Communication

Discussed with Dr. Tolliver, who sees him the same day. The findings and plan were explained to Mr. Ashe, who agreed with them; this report is held in the confidential part of the record, and he received his own copy. **S**

## Follow-up

Infectious diseases review after the six-month results, or sooner if the viral load is detectable on any check; primary care continues the three-monthly monitoring between visits. **S**

## Guideline basis

- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition), U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition), National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024), International Antiviral Society-USA (JAMA)
- Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020), HIV Medicine Association of the Infectious Diseases Society of America (Clinical Infectious Diseases)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
